NEW YORK (GenomeWeb News) - Millenium Pharmaceuticals said Tuesday it has identified a genomic biomarker during Phase II trials of a cardiovascular disease drug.
The company said it has found that 11.3 percent of patients treated with its MLN1202 monoclonal antibody had a reduction of C-reactive protein (CRP), and that CRP reductions were more likely in patients with a SNP that was identified in 53 percent of the study population.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.